Disc Medicine Inc (IRON)

Apr 9, 2025, 7:13 AM EDT - 19 days ago

Disc Medicine: Forging Ahead In Hematology

Feb 27, 2025, 8:00 AM EST - 2 months ago

Disc Medicine Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 26, 2025, 8:00 AM EST - 2 months ago

Disc Medicine to Participate in Upcoming Investor Conferences

Jan 22, 2025, 9:35 PM EST - 3 months ago

Disc Medicine Announces Pricing of $225.5 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

Jan 22, 2025, 8:10 AM EST - 3 months ago

Progress Software, Disc Medicine And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

PRGS

Jan 21, 2025, 4:01 PM EST - 3 months ago

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Jan 21, 2025, 7:45 AM EST - 3 months ago

Disc Medicine Announces Successful Type C Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP) and Shares Plans for NDA Submission

Jan 20, 2025, 7:00 PM EST - 3 months ago

Disc Medicine to Host Conference Call on Type C Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

Jan 17, 2025, 4:00 PM EST - 3 months ago

Disc Medicine Reports Inducement Grant under Nasdaq Listing Rule 5635(C)(4)

Dec 9, 2024, 12:00 PM EST - 5 months ago

Disc Medicine Presents Positive Clinical and Translational Data Across Portfolio at the 66th American Society of Hematology (ASH) Annual Meeting

Dec 8, 2024, 8:00 PM EST - 5 months ago

Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting

Nov 8, 2024, 8:30 AM EST - 6 months ago

Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc.

Nov 4, 2024, 7:50 AM EST - 6 months ago

Disc Medicine Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval

Nov 1, 2024, 4:01 PM EDT - 6 months ago

Disc Medicine to Host Conference Call on End of Phase 2 FDA Meeting for Bitopertin in Erythropoietic Protoporphyria (EPP)

Oct 25, 2024, 1:00 PM EDT - 6 months ago

Disc Medicine Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease (CKD) and Anemia at the 2024 American Society of Nephrology (ASN) Kidney Week

Oct 11, 2024, 8:00 AM EDT - 7 months ago

Disc Medicine Announces Presentation of New Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2024 American Society of Nephrology (ASN) Kidney Week

Sep 19, 2024, 8:30 AM EDT - 7 months ago

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer

Jun 14, 2024, 1:26 PM EDT - 11 months ago

Disc Medicine: Hematological Disorders Treatment Advances With DISC-0974 Progress

Jun 14, 2024, 8:03 AM EDT - 11 months ago

Disc Medicine Announces Underwritten Offering of Common Stock

Jun 14, 2024, 7:30 AM EDT - 11 months ago

Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress

May 30, 2024, 9:00 AM EDT - 11 months ago

Disc Medicine to Participate in the Jefferies Global Healthcare Conference

May 14, 2024, 10:30 AM EDT - 1 year ago

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress

May 13, 2024, 8:00 AM EDT - 1 year ago

Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference

May 9, 2024, 8:00 AM EDT - 1 year ago

Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 2, 2024, 8:01 AM EDT - 1 year ago

Top 3 Health Care Stocks You'll Regret Missing This Month - Humana (NYSE:HUM), Disc Medicine (NASDAQ:IRON)

HUM

Apr 1, 2024, 8:00 AM EDT - 1 year ago

Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)

Mar 21, 2024, 8:00 AM EDT - 1 year ago

Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 6, 2024, 4:30 PM EST - 1 year ago

Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024

Feb 26, 2024, 8:30 AM EST - 1 year ago

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer

Feb 20, 2024, 9:00 AM EST - 1 year ago

FDA Grants Orphan Drug Designation to 9MW3011

Feb 20, 2024, 8:30 AM EST - 1 year ago

Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

Feb 9, 2024, 9:00 AM EST - 1 year ago

Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera

Feb 7, 2024, 8:00 AM EST - 1 year ago

Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer

Jan 3, 2024, 5:00 PM EST - 1 year ago

Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 20, 2023, 4:30 PM EST - 1 year ago

Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board

Dec 11, 2023, 8:30 PM EST - 1 year ago

Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting

Dec 11, 2023, 12:00 PM EST - 1 year ago

Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting

Nov 14, 2023, 4:44 PM EST - 1 year ago

Disc Medicine Announces Grant of US Patent for Methods of Treating Erythropoietic Protoporphyrias with Bitopertin

Nov 9, 2023, 8:30 AM EST - 1 year ago

Disc Medicine Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 2, 2023, 9:00 AM EDT - 1 year ago

Disc Medicine Announces Multiple Presentations Across Portfolio at the 65th American Society of Hematology Annual Meeting and Key Program Updates

Oct 25, 2023, 8:42 AM EDT - 1 year ago

Disc Medicine: Rare Disease Biotech With Enormous Potential

Oct 23, 2023, 9:15 AM EDT - 1 year ago

Disc Medicine Announces Planned Departure of Chief Financial Officer Joanne Bryce

Oct 3, 2023, 8:30 AM EDT - 1 year ago

Disc Medicine Initiates a Phase 1 Study of DISC-3405 (anti-TMPRSS6 mAb) in Healthy Volunteers

Sep 21, 2023, 8:00 PM EDT - 1 year ago

FDA Grants Fast Track Designation to 9MW3011

Sep 20, 2023, 4:30 PM EDT - 1 year ago

Disc Medicine Receives FDA Fast Track Designation for MWTX-003 for the Treatment of Polycythemia Vera

Aug 22, 2023, 5:43 AM EDT - 1 year ago

Disc Medicine: Rare Disease Developer Derisking Itself

Aug 11, 2023, 8:00 AM EDT - 1 year ago

Disc Medicine Reports Second Quarter 2023 Financial Results and Provides Business Update

Jul 27, 2023, 9:00 AM EDT - 1 year ago

Disc Medicine Announces First Patient Enrolled in Phase 1/2 Clinical Trial of Bitopertin in Diamond-Blackfan Anemia (DBA)

Jun 22, 2023, 4:15 PM EDT - 2 years ago

Disc Medicine Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jun 13, 2023, 10:39 PM EDT - 2 years ago

Disc Medicine Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants